Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 16 - Net Loss Per Share (Tables)

Note 16 - Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2023

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		*Three Months Ended*								*Six Months Ended*
		*June 30,*								*June 30,*
		*2023*				*2022*				*2023*				*2022*
Numerator:
Net loss applicable to common stockholders, basic and diluted		$	(4,230	)		$	(2,978	)		$	(8,619	)		$	(7,598	)

Denominator:
Weighted-average number of shares, basic and diluted			13,637				12,884				13,467				12,807

Net loss per share, basic and diluted		$	(0.31	)		$	(0.23	)		$	(0.64	)		$	(0.59	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		*Three Months Ended*								*Six Months Ended*
		*June 30,*								*June 30,*
		*2023*				*2022*				*2023*				*2022*
Options to purchase common stock			261				307				261				307
Restricted stock units			1,555				1,066				1,555				1,066
Warrants for common stock			1,240				1,240				1,240				1,240
Total common stock equivalents			3,056				2,613				3,056				2,613